NPTX2 and Alzheimer disease: The diagnostic accuracy of NPTX2 of 71% to distinguish symptomatic from presymptomatic mutation carriers is comparable to that of neurogranin, the most evaluated synapse-derived CSF biomarker for AD.38 Its longitudinal evaluation, especially in the late-presymptomatic stage, might be more valuable than cross-sectional measurements.